Nanoparticles of biodegradable polymers for new-concept chemotherapy

Expert Review of Medical Devices

Volumn 1, Issue 1, 2004, Pages 115-125

  Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anticancer drugs; Biomaterials; Blood brain barrier; Cancer; Chemotherapeutic engineering; Controlled release; Drug delivery; Oral chemotherapy; Paclitaxel; Targeted delivery

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; COPOLYMER; CREMOPHOR; CYCLOSPORIN A; CYTOCHROME P450; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GELATIN; GLYCOPROTEIN P; HEPARIN; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PACLITAXEL; PHOSPHOLIPID DERIVATIVE; POLOXAMER; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POLYSORBATE 80; POLYVINYL ALCOHOL; ROSE BENGAL; SOLID LIPID NANOPARTICLE; TOCOFERSOLAN;

ANTINEOPLASTIC ACTIVITY; ATOMIC FORCE MICROSCOPY; BIODEGRADABLE IMPLANT; BLOOD BRAIN BARRIER; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHEMICAL ENGINEERING; CYTOTOXICITY; DEVICE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MICELLE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RESTENOSIS; REVIEW; SCANNING ELECTRON MICROSCOPY; SIDE EFFECT; TRANSMISSION ELECTRON MICROSCOPY; X RAY PHOTOELECTRON SPECTROSCOPY;

EID: 13544259954     PISSN: 17434440     EISSN: None     Source Type: Journal    
DOI: 10.1586/17434440.1.1.115     Document Type: Review

References (80)

1. Grillo-Lopez AJ. Cancer therapies crisis in the USA. Expert Rev. Anticancer Ther. 3(5), 579-582 (2003).
2. Georgoulias V, Georgoulias V. Docetaxel (taxotere) in the treatment of nonsmall cell lung cancer, Curr. Med. Chem. 9(8), 869-877 (2002).
3. Gelderblom H, Verweij J, Nooter K et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37(13), 1590-1598 (2001).
4. Langer R. Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Acc. Chem. Res. 33, 94-101 (2000).
5. Kumar MNVR. Nano- and microparticles as controlled drug delivery devices. J. Pharm. Sci. 3(2), 234-258 (2000).
6. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45 (1), 89-121 (2000).
7. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50(1), 161-177 (2000).
8. Lambert G, Fattal E, Couvreur P. Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv. Drug Deliv. Rev. 47(1), 99-112 (2001).
9. Soppimatha KS, Aminabhavi TM, Kulkarnia AR, Rudzinskib WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70(1-2), 1-20 (2001).
10. Kumar MNVP, Kumar N, Domb AJ et al. Pharmaceutical polymeric controlled drug delivery systems. Adv. Polym. Sci. 160, 45-117 (2002).
11. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54 (5), 631-651 (2002).
12. Gaur U, Sahoo SK, De TK et al. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int. J. Pharm. 202(1-2), 1-10 (2000).
13. Dellacherie E, Gref R, Quellec P. Nanospheres as new injectable drug carriers: a promising way? M S-Med. Sci. 17(5), 619-626 (2001).
14. Evora C, Soriano I, Rogers RA et al. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control. Release 51, 143-152 (1998).
15. Miglietta A, Cavalli R, Bocca C et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 210(1-2), 61-67 (2000).
16. Feng SS, Huang GF. Effects of phospholipids as emulsifiers on controlled release of paclitaxel from nanospheres of biodegradable polymers. J. Control. Release 71, 53-69 (2001).
17. Feng SS, Mu L, Win KY, Huang GF. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 11, 413-424 (2004).
18. Feng SS, Ruan G, Li QT. Liposome encapsulated microspheres of biodegradable polymers: a novel drug delivery device conceived from a combination of polymer-based and lipid-based controlled delivery systems. Biomaterials 25, 5181-5189 (2004).
19. Ruan G, Feng SS. Preparation and characterizations of PLA-PEG-PLA microspheres for controlled release of paclitaxel. Biomaterials 24, 5037-5044 (2003).
20. Dong YC, Feng SS. Paclitaxel-loaded methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles by nanoprecipitation method. Biomaterials 25(14), 2843-2849 (2004).
21. Mu L, Feng SS. Fabrication, characterization and in vitro release of paclitaxel-loaded poly(lactic-co-glycolic acid) (PLGA) nanospheres prepared by the spray dry technique with phospholipids/cholesterol as additives. J. Control. Release 76, 239-254 (2001).
22. Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent extraction/evaporation technique for fabrication of polymeric nanospheres for controlled release of paclitaxel. J. Control. Release 80, 129-144 (2002).
23. Mu L, Feng SS. A novel controlled release formulation for anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release 86(1), 33-48 (2003).
24. Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and the drug loading ratio. Pharm. Res. 20(11), 1864-1872 (2003).
25. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235(1-2), 179-192 (2002).
26. Liggins RT, Burt HM. Polyether-polyester diblock co-polymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv. Drug Deliv. Rev. 54(2), 191-202 (2002).
27. Kolodgie FD, John M, Khurana C et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 106(10), 1195-1198 (2002).
28. Fonseca C, Simoes S, Gaspar RE. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro antitumoral activity. J. Control. Release 83(2), 273-286 (2002).
29. Potineni A, Lynn DM, Langer R et al. Poly(ethylene oxide)-modified poly(β-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery J. Control. Release 86(2-3), 223-234 (2003).
30. Verdun C, Brasseur F, Vranckx H et al. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer. Chemoth. Pharm. 26(1), 13-18 (1990).
31. Yoo HS, Lee KH, Oh JE et al. In vitro and in vivo antitumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J. Control. Release 68(3), 419-431 (2000).
32. Yoo HS, Oh JE, Lee KH et al. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 16(7), 1114-1118 (1999).
33. Yang SC, Ge HX, Hu Y et al. Doxorubicin-loaded poly(butylcyanoacrylate) nanoparticles produced by emulsifier-free emulsion polymerization. J. Appl. Polym. Sci. 78(3), 517-526 (2000).
34. Janes KA, Fresneau MP, Marazuela A et al. Chitosan nanoparticles as delivery systems for doxorubicin. J. Control. Release 73(2-3), 255-267 (2001).
35. Mitra S, Gaur U, Ghosh PC et al. Tumor targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release 74(1-3), 317-323 (2001).
36. Gelperina SE, Khalansky AS, Skidan IN et al. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126(2), 131-141 (2002).
37. Yi YM, Yang TY, Pan WM. Preparation and distribution of 5-fluorouracil I-125 sodium alginate-bovine serum albumin nanoparticles. World J. Gastroenterol. 5(1), 57-60 (1999).
38. McCarron PA, Woolfson AD, Keating SM. Sustained release of 5-fluorouracil from polymeric nanoparticles. J. Pharm. Pharmacol. 52(12), 1451-1459 (2000).
39. Fishbein I, Chorny M, Rabinovich L. et al. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J. Control. Release 65(1-2), 221-229 (2000).
40. Fishbein I, Chorny M, Banai S et al. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscl. Throm. Vas. 21(9), 1434-1439 (2001).
41. Das GS, Rao GHR, Wilson RF et al. Controlled delivery of taxol from poly(ethylene glycol)-coated poly(lactic acid) microspheres. J. Biomed. Mater. Res. 55(1), 96-103 (2001).
42. Chorny M, Fishbein I, Golomb G. Drug delivery systems for the treatment of restenosis. Crit. Rev. Ther. Drug 17(3), 249-284 (2000).
43. Feng SS, Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Invited review. Chem. Engr. Sci. 58, 4087-4114 (2003).
44. Links M, Brown R. Clinical relevance of the molecular mechanisms of resistance to anticancer drugs. Expert Rev. Mol. Med. 1, 1-21 (1999).
45. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607-4612 (1998).
46. Yuan F, Dellian M, Fukumura D et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752-3756 (1995).
47. Unezaki S, Maruyama K, Hosoda JI et al. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int. J. Pharm. 144, 11-17 (1996).
48. Jain KK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control. Release 74, 7-25 (2001 C).
49. Malingre MM, Beijnen JH, Schellens JHM. Oral delivery of taxanes. Invest. New Drug 19(2), 155-162 (2001A).
50. Malingre MM, Schellens JHM, van Tellingen O et al. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after iv. administration. Anticancer Drug 11 (10), 813-820 (2000).
51. Malingre MM, Terwogt JMM, Beijnen JH et al. Phase I and pharmacokinetic study of oral paclitaxel. J. Clin. Oncol. 18(12), 2468-2475 (2000).
52. Zambaux MF, Bonneaux F, Gref R et al. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by double emulsion method. J. Control. Release 50, 31-40 (1998).
53. Couvreur P, Kante B, Roland M et al. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphology and sorptive properties. J. Pharm. Pharmacol. 31, 331-332 (1979).
54. Behan N, Birkinshaw C, Clarke N. Poly n-butyl cyanoacrylate nanoparticles: A mechanistic study of polymerization and particle formation. Biomaterials 22(11), 1335-1344 (2001).
55. De TK, Hoffman AS. A reverse microemulsion polymerization method for preparation of bioadhesive polyacrylic acid nanoparticles for mucosal drug delivery: loading and release of timolol maleate. Artif. Cell. Blood Sub. 29(1), 31-46 (2001).
56. Desai MP, Labhasetwar V, Walter E et al. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharmaceut. Res. 14(11), 1568-1573 (1997).
57. McClean S, Prosser E, Meehan E et al. Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci. 6, 153-163 (1998).
58. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv. Drug Deliv. Rev. 34, 221-233 (1998).
59. Jung T, Kamm W, Breitenbach A et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50, 147-160 (2000).
60. De Jaeghere F, Allemann E, Leroux JC et al. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: Influence on physical stability and in vitro cell uptake. Pharm. Res. 16(6), 859-866 (1999).
61. Coester C, Kreuter J, von Briesen H et al. Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA). Int. J. Pharm. 196(2), 147-149 (2000).
62. Qaddoumi MG, Ueda H, Yang J et al. The mechanism of uptake of biodegradable PLGA nanoparticles in conjunctival epithelial cell layers. Invest. Ophth. Vis. Sci. 42(4), 2628 (2001).
63. Behrens I, Pena AIV, Alonso MJ et al. Comparative uptake studies of bioadhesive and nonbioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 19(8), 1185-1193 (2002).
64. Pietzonka P, Rothen-Rutishauser B, Langguth P et al. Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to Caco-2 monolayers mimics particle uptake. Pharmaceut. Res. 19(5), 595-601 (2002).
65. Sakurai K, Nakada Y, Nakamura T et al. Preparation and characterization of polylactide-poly(ethylene glycol)-polylactide triblock polymers and a preliminary in vivo examination of the blood circulation time for the nanoparticles made therefrom. J. Macromol. Sci. Pure 36(12), 1863-1877 (1999).
66. Tobio M, Sanchez A, Vila A et a.l The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid Surface B 18(3-4), 315-323 (2000).
67. Chen DB, Yang TZ, Lu WL et al. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. 49(11), 1444-1447 (2001 ).
68. Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterization and in vivo evaluation. J. Control. Release 70(3), 353-363 (2001).
69. Jiao YY, Ubrich N, Marchand-Arvier M et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105(2), 230-235 (2002).
70. Au JLS, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J. Control Release 78(1-3), 81-95 (2002).
71. Au JLS, Jang SH, Zheng J et al. Determinants of drug delivery and transport to solid tumors. J. Control. Release 74(1-3), 31-46 (2001).
72. Loos WJ, Szebeni J, ten Tije AJ et al. Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel. Anticancer Drug 13(7), 767-775 (2002).
73. O'Connor PW, Lee L, Moscarello M et al. A Phase I study of micellar paclitaxel in the treatment of secondary progressive multiple sclerosis. Ann. Neurol. 46(3), 470-470 (1999).
74. Theresa MA, Pieter RC. Drug delivery systems: entering the mainstream. Science 303, 1818-1822 (2004).
75. Kim SY, Lee YM, Baik DJ et al. Toxic characteristics of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials 24(1), 55-63 (2003).
76. Shabbits JA, Chiu GNC, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J. Control. Release 84(3), 161-170 (2002).
77. Khin YW, Feng SS. effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. In press (2004).
78. Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of effects of molecular weight and degree of deacetylation. Pharm. Res, 21(2), 344-353 (2004).
79. Mo Y, Lim LY. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. J. Pharm. Sci. 93(1), 20-28 (2004).
80. Wilhelm C, Billotey C, Roger J et al. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 24(6), 1001-1011 (2003).